Search results
Results From The WOW.Com Content Network
PSA Doubling Time can be an indicator of biochemical and clinical progression. This tool predicts the changes in PSA levels over time. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy.
PSA is useful for detecting a relapse of prostate cancer after surgery or radiation. After prostate cancer surgery, PSA is normally undetectable, and even small rises could point to a recurrence. After curative radiation, the PSA generally stays under 1.0 long-term. However, there are exceptions.
A high Decipher genomic classifier score, increasing CAPRA-S score, and PSA doubling time of less than six months were associated with a greater likelihood of receiving salvage treatment. “These results give patients hope that if PSA becomes detectable, the outcome is still likely to be quite good,” Carroll said.
For patients who have undergone radical prostatectomy, a rising PSA level suggests evidence of residual or recurrent prostate cancer. Many men remain free of clinical disease for an extended time after biochemical failure following radical prostatectomy for clinically localized prostate cancer.
Your PSA should fall to a very low or even undetectable level within a couple of months after radical prostatectomy. Because some PSA can remain in the blood for several weeks after surgery, even if all of the prostate cells were removed, doctors often advise waiting at least 6 to 8 weeks after surgery before checking the PSA level.
Only the prostate gland releases PSA, so your numbers should drop to almost zero within 4 weeks after your surgery. A test result above 0.2 ng/mL a few months after your procedure could be...
One method to improve our ability to predict prognosis, PSA doubling time (PSADT), is simple to determine and currently available. In this issue of the Proceedings, Roberts et al 1 examine postoperative PSADT in 587 patients with untreated biochemical recurrence after radical prostatectomy (patients were censored at the time of additional ...
In men with biochemically-recurrent prostate cancer, prostate-specific antigen doubling time ≤ 7.5 months, prostate-specific antigen ≥ 0.5 ng/mL, and Gleason score are independent predictors of metastasis-free survival on multivariable analysis.
The most important values to enter are the date/PSA value for each PSA measured over the last 12 months. Alternately, if at least three PSA values are available, enter all PSA values after receiving radical prostatectomy, beginning with the lowest PSA value.
The aim of this study was to investigate the association of prostate-specific antigen (PSA) values on metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) and PSA doubling time (PSADT) < 12 months.